Healthcare AI · Clinical operations and oncology support
Ankr Health
A Houston company that started by helping cancer patients track chemo side effects and has since rebuilt itself twice, first as a pharma-facing prediction platform, now as a set of generative AI agents meant to staff a clinic's front desk, scribing and billing.
A call from the ER
Three years before Ankr won its first pitch competition, Dr. Arpit Rao had a patient in his oncology clinic who seemed to have every advantage. She was sharp, she had gotten a second opinion, and as the CEO of her own company she had the means to travel for treatment. A few months into oral chemotherapy, an ER doctor called Rao with a panicked report: his patient had a life-threatening brain hemorrhage, a known but rare side effect of a blood pressure spike during treatment, buried in six pages of other potential reactions.
“I said if this smart, educated really supported and well-resourced person couldn’t do it, then there are 17 million cancer patients in this country who need our help, too,” Rao told the Houston Chronicle in 2021.
That call became the reason he spent, in the paper’s words, the next several years developing Ankr: a system meant to warn patients about side effects before they happen, and to get them to care faster when something goes wrong.
The problem, twice stated
Ankr’s Y Combinator listing frames the company’s current problem this way: “Adoption of Telehealth 1.0 has dropped to <5% because it’s inefficient and unintelligent.” The pitch is that generative AI can recreate the functions of clinic staff, front desk, medical assistants, scribes, so doctors can run a virtual clinic on demand.
That is a different problem from the one Rao described to the Chronicle in 2021, about cancer patients missing warning signs buried in dense medication information. Both versions point at the same underlying gap: clinical staff time is scarce, and much of what fills it does not require a doctor. What has changed is which piece of that gap Ankr is trying to fill, and who it sells to.
Founders
Dr. Arpit Rao, who also goes by Ray, describes himself as “a recovering cancer Doc” and “a 3x founder backed by YC and Medtech Innovator.” Independent video records from urotoday.com show him presenting oncology research, including a Phase I trial on prostate cancer treatment combinations. Ankr’s own about page calls him a “Renowned ONCOLOGIST.”
Shivani Rao is named as Ankr’s other co-founder by Tracxn, a private company data provider. No independent profile, professional background, or role description for her was found in this research.
Three products in six years
The company’s earliest public trace is an iOS app, Ankr Cancer Care Companion, whose App Store listing shows a copyright of “2018 Medconsult LLC,” a name that does not appear anywhere else in this research. By late 2021, per the Houston Chronicle, that product already served 26 clinics and more than 50,000 patients, and Rao hoped to double that reach within a year. In November 2021, Ankr won the inaugural Startup Showcase at Rice University’s Ion innovation hub, taking $10,000 in cash and free legal services from Baker Botts.
Tracxn records a legal entity, Ankr Health Corp., incorporated March 4, 2022, with a $500,000 seed round closing March 29, 2022. Parsers.vc lists Y Combinator and WorldQuant Ventures as investors, and Y Combinator’s own listings confirm Ankr Health in its Winter 2022 (W22) batch. In June 2023, Ankr was one of four Houston startups, and one of 61 worldwide out of nearly 1,200 applicants, selected for the MedTech Innovator accelerator cohort, per InnovationMap.
By 2025 the company was describing itself differently again. A company landing page built for JPMorgan’s healthcare conference introduces “Ankr 4X,” a platform aimed at pharmaceutical companies rather than clinics, built around a published side effect prediction model and, per an independent podcast description, “first major deal with AstraZeneca”. By 2026, Ankr’s main website had shifted again, to “Ankr VCX,” a set of named AI agents, Mira for phone calls, Sol for scribing, Frank, Gina and Gary for triage, prior authorization and billing, sold to medical practices as an alternative to hiring or offshoring staff.
What is proven, and what is still claimed
| Evidence | What the record shows | Source type |
|---|---|---|
| Y Combinator | Ankr Health is listed in Y Combinator’s Winter 2022 (W22) batch, confirmed on both Y Combinator’s company page and its Work at a Startup jobs page. | Public record |
| Ion Startup Showcase, Nov 2021 | Won the inaugural competition at Rice University’s Ion, plus $10,000 and free legal services, reported by the Houston Chronicle. The same article states Ankr already served 26 clinics and more than 50,000 patients. | Independent |
| MedTech Innovator, 2023 | One of 61 companies selected for the 2023 cohort from nearly 1,200 applicants, and one of four Houston startups chosen that year, per Houston’s InnovationMap. | Independent |
| Seed funding, Mar 2022 | Tracxn records a $500,000 seed round closing Mar 29, 2022, with Y Combinator and, per Parsers.vc, WorldQuant Ventures as investors. Exact valuation is redacted in Tracxn’s public view. | Independent, unverified |
| SEC Form D | A direct EDGAR company search for “Ankr Health” returns no results. The only “Ankr” entity with a Form D on file is an unrelated blockchain company’s investment vehicle. | Public record |
| FDA and clinical trials | No 510(k), PMA, or ClinicalTrials.gov registration found for Ankr or Ankr Health. | Not found |
| Named clinic and health system customers | Company materials describe being “live in a 22-clinic health system in Minnesota and Wisconsin” and working with “over 300 additional Doctors” in Texas, Florida, Arizona, California and Michigan, plus a pharma contract following “1.5 year diligence from 2 of the world’s top 5 pharma companies.” None of these customers is named. | Company-stated |
| Revenue | GetLatka estimates $2.3 million in 2024 revenue, but the same page also lists a $4.5 million estimate for June 2024, a drop of roughly half within the same year on the page’s own numbers. GetLatka separately states no funding has been reported for Ankr Health, which does not match Tracxn’s seed round record. | Conflicting estimates |
Read plainly: the accelerator history and the 2021 local award are the most solid facts here, confirmed by outlets with no financial stake in the company. Everything about revenue, funding total, and named customers comes from the company itself or from private data providers whose own numbers disagree.
What to watch
- Whether any of the clinics, health systems, or pharma partners Ankr describes get named, by the company or by a partner.
- A Form D or other public funding record, since none has appeared for Ankr Health as of this research.
- Whether the pivot to “Ankr VCX” AI staffing agents produces independent coverage, case studies, or EHR marketplace listings beyond the company’s own site.
- Consistency between the company’s own revenue and funding statements and third-party estimates, which currently disagree.
In their words
“I said if this smart, educated really supported and well-resourced person couldn’t do it, then there are 17 million cancer patients in this country who need our help, too.”
Dr. Arpit Rao, founder, Houston Chronicle, 2021 · Independent
“Entrepreneurship can be isolating. You believe in it, but you don’t always get validation.”
Dr. Arpit Rao, founder, Houston Chronicle, 2021 · Independent
“Adoption of Telehealth 1.0 has dropped to <5% because it’s inefficient and unintelligent.”
Ankr Health, Y Combinator company page, 2026 · Company-stated
“Hi there. I am Ray, a recovering cancer Doc. And a 3x founder backed by YC and Medtech Innovator.”
Ray Rao, Ankr JPM 2025 conference page · Company-stated
“When someone gets diagnosed with cancer, we (the health system) overwhelm them with important information. I always thought that there has to be a better way to give patients what they need, when they need.”
Dr. Arpit Rao, founder, Ankr about page · Company-stated
“We explore Arpit’s path from running FDA-level clinical trials to translating those experiences into a startup that predicts treatment-limiting side effects before they occur.”
The Healthcare Theory podcast episode description, Apr 20, 2025 · Independent
“The startup (whose name is pronounced ‘anchor’) provides a caregiving platform for cancer patients in the U.S.”
InnovationMap, John Egan, Jun 14, 2023 · Independent
Related companies
Sources
- IndependentCancer care firm Ankr wins Ion’s first startup showcase
- Independent4 Houston startups selected for preeminent medtech accelerator
- IndependentFrom Oncology to Building AI for Pharma, episode description
- Public recordAnkr Health: Virtualizing brick-mortar infrastructures of clinics w/ generative AI
- Public recordJobs at Ankr Health (W22)
- Public recordEDGAR company search, “ankr health”, no results
- Public recordEDGAR company search, “ankr”, Form D filings
- Independent, unverifiedAnkr company profile and funding record
- Independent, unverifiedAnkr Health (YC W22), investors and press mentions
- Independent, unverifiedAnkr Health Revenue 2024: $2.3M Est. ARR
- Independent, unverifiedAnkr Health funding and signals
- CompanyAnkr VCX, AI Workforce for Medical Practices, home page
- CompanyElevated patient care, home page
- CompanyAnkr for your health system, partner page
- CompanyThe team you can trust, about us page
- CompanyRay Rao at JPM 2025, Ankr 4X conference page
- CompanyAnkr, Cancer Care Companion, App Store listing
- IndependentPhase I RAMP study video, presenter Arpit Rao
Profile researched and written by Healthcare Discovery. Last updated September 29, 2026.
